Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBS NASDAQ:MOTS NASDAQ:NVIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBSIntelligent Bio Solutions$1.47-0.3%$1.76$1.00▼$3.00$10.12M4.59176,926 shs42,786 shsMOTSMotus GI$0.00$0.00▼$0.05$1K1.015,206 shs1,000 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBSIntelligent Bio Solutions+2.08%-2.00%-16.95%+14.40%+25.64%MOTSMotus GI0.00%0.00%-66.67%-66.67%-99.63%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINBSIntelligent Bio Solutions0.9913 of 5 stars0.03.00.00.03.00.01.3MOTSMotus GI0.0662 of 5 stars0.01.00.00.01.10.00.6NVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBSIntelligent Bio Solutions 0.00N/AN/AN/AMOTSMotus GI 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBSIntelligent Bio Solutions$3.11M3.26N/AN/A$2.37 per share0.62MOTSMotus GI$319K0.00N/AN/A$1.74 per share0.00NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBSIntelligent Bio Solutions-$10.16MN/A0.004.19N/A-319.85%-176.55%-93.89%9/17/2025 (Estimated)MOTSMotus GI-$12.87M-$15.64N/AN/AN/AN/AN/AN/AN/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBSIntelligent Bio SolutionsN/A1.120.97MOTSMotus GIN/AN/AN/ANVIVInVivo TherapeuticsN/A14.3014.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBSIntelligent Bio Solutions32.97%MOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%Insider OwnershipCompanyInsider OwnershipINBSIntelligent Bio Solutions0.28%MOTSMotus GI0.34%NVIVInVivo Therapeutics2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBSIntelligent Bio Solutions106.91 million6.89 millionNot OptionableMOTSMotus GI305.77 million5.75 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableMOTS, INBS, and NVIV HeadlinesRecent News About These CompaniesAngelini Ventures co-leads Series A financing in Neumirna TherapeuticsJanuary 8, 2025 | pharmatimes.comP10 Best MBAs For Entrepreneurs In The World | Stanford, Harvard & MoreOctober 21, 2024 | businessbecause.comBBankruptcies, layoffs and closures: The big decisions facing orthopedic leadersOctober 19, 2024 | beckersspine.comBAntivirals: Current State of the ArtSeptember 3, 2024 | medscape.comMSpinal Cord Injury Treatment Market Size to Worth USD 11 Bn by 2032August 9, 2024 | finance.yahoo.comInVivo Therapeutics Holdings Co (NVIVQ)May 26, 2024 | finance.yahoo.comInVivo Therapeutics Holdings Corp (NVIVQ)May 17, 2024 | investing.comInterview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?April 8, 2024 | outsourcing-pharma.comOGut health supplements are everywhere – but which are the best ones for *you*?March 28, 2024 | msn.comDrug discovery and global player, Cresset, moves team into Boston marking major turning pointMarch 12, 2024 | outsourcing-pharma.comOInVivo Therapeutics Holdings CorporationFebruary 14, 2024 | cnn.comInVivo Therapeutics Holdings Corp.February 14, 2024 | wsj.comFirm Retention Summary: InVivo Therapeutics HoldingsFebruary 13, 2024 | wsj.comInVivo Therapeutics Holdings Corp (NVIV)February 7, 2024 | investing.comBob Langer-founded device-maker declares bankruptcyFebruary 6, 2024 | bizjournals.comWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?February 6, 2024 | investorplace.comInVivo Therapeutics Shares Plumb New Depths After Bankruptcy FilingFebruary 1, 2024 | marketwatch.comSpinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market InsightsJanuary 31, 2024 | prnewswire.co.ukPInVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security HoldersJanuary 5, 2024 | cbonds.comCInVivo Biosystems Secures New Investment to Accelerate CRISPR InnovationJanuary 4, 2024 | pharmiweb.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMOTS, INBS, and NVIV Company DescriptionsIntelligent Bio Solutions NASDAQ:INBS$1.46 -0.01 (-0.34%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Motus GI NASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Pulls Back Into a Screaming Buy Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access